Back to results
US 10,894,075 B2Granted
Gla domains as targeting agents
AssigneeGladiator Biosciences, Inc.
InventorsMaxine Bauzon, Terry Hermiston
Life of this patent
Estimating the term…
Abstract
The disclosure relates to the recombinant Gla domain proteins and their use targeting phosphatidylserine (PtdS) moieties on the surface of cells, particularly those expressing elevated levels of PtdS, such as cells undergoing apoptosis. These proteins can be linked to both diagnostic and therapeutic payloads, thereby permitting identification and treatment of cells expression elevated PtdS.
Claims14
A method of treating a viral disease in a subject comprising administering to said subject an isolated human polypeptide that targets cell membrane phosphatidylserine comprising:
- (a) a protein S gamma-carboxyglutamic-acid (Gla) domain, and
- (b) a protein S EGF binding domain,
- wherein said polypeptide (i) comprises 5-15 Gla residues, (ii) lacks both a protease domain and a hormone-binding domain, and (iii) is conjugated to a therapeutic agent selected from an anti-viral agent and a toxin.
Dependencies are inferred from the claim text.